Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Protonix Settlement May Deter Price Bundling

This article was originally published in The Pink Sheet Daily

Executive Summary

$784.6m fine will resolve claims that Wyeth subsidiary paid hospitals steep discounts if they purchased both oral and IV Protonix while reporting higher prices to the government.

Advertisement

Related Content

Pharma Deals With The DOJ
Wyeth Rapamune Off-Label Marketing Settlement Will Not Alter Pfizer’s CIA
Pfizer Settles Protonix Off-Label Allegations – Pricing Investigation Still Unresolved
Bundling of Wyeth Protonix Sales to Hospitals Tied to Medicaid Fraud, DoJ Says
Aranesp Contracts Revised: 50% Share Of ESA Purchases Qualifies Clinics For Best Discount

Related Companies

Advertisement
UsernamePublicRestriction

Register